Supernus and Indivior file investor presentation for proposed merger of equals; terms undisclosed

SUPERNUS PHARMACEUTICALS, INC.

Conference call held August 3, 2026 at 8:30 a.m. ET to discuss merger of equals.
Merger of equals aims to create a diversified CNS biopharmaceutical leader with significant scale.
Forward-looking statements reference a special dividend funded by additional indebtedness; amount not specified.
Indivior to file Form S-4 with joint proxy statement/prospectus for stockholder vote.
Investor presentation filed with SEC on August 3, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.